Development of a Novel Humanized Monoclonal Antibody to Secreted Frizzled-Related Protein-2 That Inhibits Triple-Negative Breast Cancer and Angiosarcoma Growth In Vivo

  • Denise Garcia
  • Patrick Nasarre
  • Ingrid V. Bonilla
  • Eleanor Hilliard
  • Yuri K. Peterson
  • Laura Spruill
  • Anne-Marie Broome
  • Elizabeth G. Hill
  • Jason T. Yustein
  • Shikhar Mehrotra
  • Nancy Klauber-DeMoreEmail author
Translational Research and Biomarkers



We previously reported that secreted frizzled-related protein-2 (SFRP2) is expressed in a variety of tumors, including sarcoma and breast carcinoma, and stimulates angiogenesis and inhibits tumor apoptosis. Therefore, we hypothesized that a humanized SFRP2 monoclonal antibody (hSFRP2 mAb) would inhibit tumor growth.


The lead hSFRP2 antibody was tested against a cohort of 22 healthy donors using a time course T-cell assay to determine the relative risk of immunogenicity. To determine hSFRP2 mAb efficacy, nude mice were subcutaneously injected with SVR angiosarcoma cells and treated with hSFRP2 mAb 4 mg/kg intravenously every 3 days for 3 weeks. We then injected Hs578T triple-negative breast cells into the mammary fat pad of nude mice and treated for 40 days. Control mice received an immunoglobulin (Ig) G1 control. The SVR and Hs578T tumors were then stained using a TUNEL assay to detect apoptosis.


Immunogenicity testing of hSFRP2 mAb did not induce proliferative responses using a simulation index (SI) ≥ 2.0 (p < 0.05) threshold in any of the healthy donors. SVR angiosarcoma tumor growth was inhibited in vivo, evidenced by significant tumor volume reduction in the hSFRP2 mAb-treated group, compared with controls (n = 10, p < 0.001). Likewise, Hs578T triple-negative breast tumors were smaller in the hSFRP2 mAb-treated group compared with controls (n = 10, p < 0.001). The hSFRP2 mAb treatment correlated with an increase in tumor cell apoptosis (n = 11, p < 0.05). Importantly, hSFRP2 mAb treatment was not associated with any weight loss or lethargy.


We present a novel hSFRP2 mAb with therapeutic potential in breast cancer and sarcoma that has no effect on immunogenicity.



This work was supported by funding from the Department of Defense (W81XWH-18-1-0007) to NKD and AMB; the Sarcoma Foundation of American (NKD); R21CA137725, R01CA138930 to SM; The Cancer Prevention and Research Institute of Texas (CPRIT), WWWW Foundation, Inc. (QuadW), The St. Baldrick’s Foundation to JTY, and NIH T32 Grant CA193201. Support from the Hollings Cancer Center and Biostatistics Shared Resources (partly supported by P30 CA138313) at the Medical University of South Carolina is also acknowledged.


Novel Targets for Regulation of Angiogenesis, US Patent No. 8,734,789. Inventor: Nancy Klauber-DeMore, MD. Combination therapy of a humanized antibody to secreted frizzled-related 2 with PD-1 inhibition for the treatment of cancer. US Provisional App. No. 62/737,155. Inventor: Nancy Klauber-DeMore, MD. Dr. Klauber-DeMore is co-founder, shareholder, Chief Scientific Officer, and Board Member of Enci Therapeutics, Inc.

Supplementary material

10434_2019_7800_MOESM1_ESM.pdf (133 kb)
Supplementary material 1 (PDF 133 kb)
10434_2019_7800_MOESM2_ESM.pdf (6.9 mb)
Supplementary material 2 (PDF 7088 kb)


  1. 1.
    Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci. 2003;116(Pt 13):2627–34.CrossRefGoogle Scholar
  2. 2.
    Yamamura S, Kawakami K, Hirata H, et al. Oncogenic functions of secreted frizzled-related protein 2 in human renal cancer. Mol Cancer Ther. 2010;9(6):1680–7.CrossRefGoogle Scholar
  3. 3.
    Esteve P, Sandonis A, Ibanez C, Shimono A, Guerrero I, Bovolenta P. Secreted frizzled-related proteins are required for Wnt/beta-catenin signalling activation in the vertebrate optic cup. Development. 2011;138(19):4179–84.CrossRefGoogle Scholar
  4. 4.
    Gehmert S, Sadat S, Song YH, Yan Y, Alt E. The anti-apoptotic effect of IGF-1 on tissue resident stem cells is mediated via PI3-kinase dependent secreted frizzled related protein 2 (Sfrp2) release. Biochem Biophys Res Commun. 2008;371(4):752–5.CrossRefGoogle Scholar
  5. 5.
    Lee JL, Chang CJ, Wu SY, Sargan DR, Lin CT. Secreted frizzled-related protein 2 (SFRP2) is highly expressed in canine mammary gland tumors but not in normal mammary glands. Breast Cancer Res Treat. 2004;84(2):139–49.CrossRefGoogle Scholar
  6. 6.
    Melkonyan HS, Chang WC, Shapiro JP, et al. SARPs: a family of secreted apoptosis-related proteins. Proc Natl Acad Sci USA. 1997;94(25):13636–41.CrossRefGoogle Scholar
  7. 7.
    Mirotsou M, Zhang Z, Deb A, et al. Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Proc Natl Acad Sci USA. 2007;104(5):1643–8.CrossRefGoogle Scholar
  8. 8.
    Courtwright A, Siamakpour-Reihani S, Arbiser JL, et al. Secreted frizzle-related protein 2 stimulates angiogenesis via a calcineurin/NFAT signaling pathway. Cancer Res. 2009;69(11):4621–8.CrossRefGoogle Scholar
  9. 9.
    Siamakpour-Reihani S, Caster J, Bandhu ND, et al. The role of calcineurin/NFAT in SFRP2 induced angiogenesis-a rationale for breast cancer treatment with the calcineurin inhibitor tacrolimus. PLoS One. 2011;6(6):e20412.CrossRefGoogle Scholar
  10. 10.
    Fontenot E, Rossi E, Mumper R, et al. A novel monoclonal antibody to secreted frizzled-related protein 2 inhibits tumor growth. Mol Cancer Ther. 2013;12(5):685–95.CrossRefGoogle Scholar
  11. 11.
    Techavichit P, Gao Y, Kurenbekova L, Shuck R, Donehower LA, Yustein JT. Secreted Frizzled-Related Protein 2 (sFRP2) promotes osteosarcoma invasion and metastatic potential. BMC Cancer. 2016;16(1):869.CrossRefGoogle Scholar
  12. 12.
    Singh S, Vinson C, Gurley CM, et al. Impaired Wnt signaling in embryonal rhabdomyosarcoma cells from p53/c-fos double mutant mice. Am J Pathol. 2010;177(4):2055–66.CrossRefGoogle Scholar
  13. 13.
    Tanaka M, Homme M, Yamazaki Y, Shimizu R, Takazawa Y, Nakamura T. Modeling alveolar soft part sarcoma unveils novel mechanisms of metastasis. Cancer Res. 2017;77(4):897–907.CrossRefGoogle Scholar
  14. 14.
    Roth W, Wild-Bode C, Platten M, et al. Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. Oncogene. 2000;19(37):4210–20.CrossRefGoogle Scholar
  15. 15.
    Oshima T, Abe M, Asano J, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood. 2005;106(9):3160–5.CrossRefGoogle Scholar
  16. 16.
    Sun Y, Zhu D, Chen F, et al. SFRP2 augments WNT16B signaling to promote therapeutic resistance in the damaged tumor microenvironment. Oncogene. 2016;35(33):4321–34.CrossRefGoogle Scholar
  17. 17.
    Xiao X, Xiao Y, Wen R, et al. Promoting roles of the secreted frizzled-related protein 2 as a Wnt agonist in lung cancer cells. Oncol Rep. 2015;34(5):2259–66.CrossRefGoogle Scholar
  18. 18.
    Kaur A, Webster MR, Marchbank K, et al. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. 2016;532(7598):250–4.CrossRefGoogle Scholar
  19. 19.
    Tsuruta JK, Klauber-DeMore N, Streeter J, et al. Ultrasound molecular imaging of secreted frizzled related protein-2 expression in murine angiosarcoma. PloS One. 2014;9(1):e86642.CrossRefGoogle Scholar
  20. 20.
    Cheng HC. The power issue: determination of KB or Ki from IC50. A closer look at the Cheng–Prusoff equation, the Schild plot and related power equations. J Pharmacol Toxicol Methods. 2001;46(2):61–71.CrossRefGoogle Scholar
  21. 21.
    Arbiser JL, Moses MA, Fernandez CA, et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci USA. 1997;94(3):861–6.CrossRefGoogle Scholar
  22. 22.
    Gabrielsson J, Weiner D. Non-compartmental analysis. Methods Mol Biol. 2012;929:377–89.CrossRefGoogle Scholar
  23. 23.
    Arbiser JL, Bonner MY, Berrios RL. Hemangiomas, angiosarcomas, and vascular malformations represent the signaling abnormalities of pathogenic angiogenesis. Curr Mol Med. 2009;9(8):929–34.CrossRefGoogle Scholar
  24. 24.
    Walter-Yohrling J, Morgenbesser S, Rouleau C, et al. Murine endothelial cell lines as models of tumor endothelial cells. Clin Cancer Res. 2004;10(6):2179–89.CrossRefGoogle Scholar
  25. 25.
    Schoffski P, Cornillie J, Wozniak A, Li H, Hompes D. Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease. Oncol Res Treat. 2014;37(6):355–62.CrossRefGoogle Scholar
  26. 26.
    Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. Lancet Oncol. 2010;11(10):983–91.CrossRefGoogle Scholar
  27. 27.
    Lorigan P, Verweij J, Papai Z, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 2007;25(21):3144–50.CrossRefGoogle Scholar
  28. 28.
    Fury MG, Antonescu CR, Van Zee KJ, Brennan MF, Maki RG. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J. 2005;11(3):241–7.CrossRefGoogle Scholar
  29. 29.
    Charafe-Jauffret E, Ginestier C, Monville F, et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene. 2006;25(15):2273–84.CrossRefGoogle Scholar
  30. 30.
    Chung CH, Bernard PS, Perou CM. Molecular portraits and the family tree of cancer. Nat Genet. 2002;32(Suppl):533–40.CrossRefGoogle Scholar
  31. 31.
    Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10(6):515–27.CrossRefGoogle Scholar
  32. 32.
    Riaz M, van Jaarsveld MT, Hollestelle A, et al. miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs. Breast Cancer Res. 2013;15(2):R33.CrossRefGoogle Scholar
  33. 33.
    Dai X, Cheng H, Bai Z, Li J. Breast cancer cell line classification and its relevance with breast tumor subtyping. J Cancer. 2017;8(16):3131–41.CrossRefGoogle Scholar
  34. 34.
    Esses KM, Hagmaier RM, Blanchard SA, Lazarchick JJ, Riker AI. Carcinosarcoma of the breast: two case reports and review of the literature. Cases J. 2009;2(1):15.CrossRefGoogle Scholar
  35. 35.
    Bhati R, Patterson C, Livasy CA, et al. Molecular characterization of human breast tumor vascular cells. Am J Pathol. 2008;172(5):1381–90.CrossRefGoogle Scholar
  36. 36.
    Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561.CrossRefGoogle Scholar
  37. 37.
    Ghosn M, El Rassy E, Kourie HR. Immunotherapies in sarcoma: updates and future perspectives. World J Clin Oncol. 2017;8(2):145–50.CrossRefGoogle Scholar
  38. 38.
    Cancer Research Institute. How is immunotherapy changing the outlook for patients with sarcoma? 2016. Accessed 3 Aug 2019.

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Denise Garcia
    • 1
  • Patrick Nasarre
    • 1
  • Ingrid V. Bonilla
    • 1
  • Eleanor Hilliard
    • 1
  • Yuri K. Peterson
    • 2
  • Laura Spruill
    • 3
  • Anne-Marie Broome
    • 4
  • Elizabeth G. Hill
    • 5
  • Jason T. Yustein
    • 6
  • Shikhar Mehrotra
    • 1
  • Nancy Klauber-DeMore
    • 1
    Email author
  1. 1.Department of SurgeryMedical University of South CarolinaCharlestonUSA
  2. 2.Department of Drug Discovery and Biomedical Sciences, College of PharmacyMedical University of South CarolinaCharlestonUSA
  3. 3.Department of PathologyMedical University of South CarolinaCharlestonUSA
  4. 4.Department of Cell and Molecular PharmacologyMedical University of South CarolinaCharlestonUSA
  5. 5.Department of Public Health SciencesMedical University of South CarolinaCharlestonUSA
  6. 6.Department of Pediatrics, Texas Children’s Cancer and Hematology CentersBaylor College of MedicineHoustonUSA

Personalised recommendations